About Valence Advantage

Valence Life Sciences is a leading life sciences investment firm focused on late-stage private and micro-cap public drug development companies. Valence Advantage Life Sciences Fund II’s targeted late-stage investment strategy – in conjunction with the team’s experience, insight, and disciplined approach – has produced successful results for both its investors and portfolio companies.

Valence Advantage Life Sciences Fund II was established in 2012 by Managing Directors, Eric W. Roberts and A. Rachel Leheny, Ph.D. – one of Wall Street’s premier life sciences investment banking and research teams. Fund II is the successor to Caxton Advantage Life Sciences Fund I which Mr. Roberts and Dr. Leheny began investing in 2006 with the same investment strategy. Valence Advantage Life Sciences was formed as an entity independent of an affiliate of Caxton Associates, a New York-based trading and investment firm.  Dr. Leheny, Mr. Roberts and their team will continue to manage Caxton Advantage’s nine portfolio companies.